– LINZESS® (linaclotide) EUTRx prescription demand growth of 11% year-over-year –
– Plans to pursue apraglutide rolling NDA review; expects to complete submission in the first quarter of 2025 –
– On track to deliver CNP-104 topline results in the third quarter of 2024 –
– Revises FY 2024 financial guidance due to continued LINZESS pricing pressure associated with higher-than-expected Medicaid utilization trends –
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.